GlassScriptPhysician profile
Mindy Ann Noll
NPI 1265403356
$7,870.19
in general payments reported to CMS, 2019-2025
55 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $724 · 2021: $1,149 · 2022: $1,239 · 2023: $964 · 2024: $1,398 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,799 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,798.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.80 | 2021-2025 | |
| Pfizer INC. | $863.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $758.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $711.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $616.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $577.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $325.00 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $309.14 | 2019-2024 | Xarelto |
| Amgen INC. | $258.93 | 2019-2024 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.46 | 2019-2025 | Jardiance |
| Abbott Laboratories | $166.37 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $163.61 | 2019-2022 | |
| Allergan, INC. | $154.08 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.89 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $151.32 | 2019-2025 | Capvaxive, Gardasil 9, Enflonsia |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Noll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.